What medications are similar to Orlissa (letrozole) for ovulation induction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Medications Similar to Orlissa for Ovulation Induction

Clomiphene citrate is the first-line medication similar to letrozole (not Orlissa) for ovulation induction, with letrozole itself being superior in efficacy. I need to clarify an important point: Orlissa is actually elagolix, a GnRH antagonist used for endometriosis, not letrozole. However, based on the context provided, I'll address medications similar to letrozole for ovulation induction.

Primary Alternatives to Letrozole

Clomiphene Citrate (First-Line Alternative)

Clomiphene citrate remains the most established alternative to letrozole for ovulation induction 1, 2. In women with PCOS attempting to conceive, clomiphene achieves approximately 80% ovulation rates with 50% of those patients conceiving 1. However, recent evidence shows letrozole is superior:

  • Live birth rates: Letrozole achieves higher rates than clomiphene (OR 1.68,95% CI 1.42-1.99; NNTB = 10) 3
  • Pregnancy rates: Letrozole shows 56% higher odds (OR 1.56,95% CI 1.37-1.78) 3
  • Monofollicular development: Letrozole produces 68.4% monofollicular growth versus 44.8% with clomiphene, reducing multiple pregnancy risk 4

Tamoxifen (Alternative SERM)

Tamoxifen serves as an acceptable alternative to clomiphene, particularly when combined with gonadotropins 5. It functions similarly as a selective estrogen receptor modulator but may be preferred in specific hormone-sensitive contexts 5.

Second-Line Options

Gonadotropins (FSH/HMG)

When clomiphene or letrozole fail, low-dose gonadotropin therapy (≤75 IU) is recommended 1, 6:

  • Induces high rates of monofollicular development
  • Lower risk of ovarian hyperstimulation syndrome (OHSS) with low-dose protocols
  • Significantly higher pregnancy rates than anti-estrogens (OR 1.8,95% CI 1.2-2.7) 6
  • Critical caveat: Higher doses show similar pregnancy rates but substantially increase multiple pregnancy rates (3.6-12.5%) 6

Combination Therapy

Letrozole combined with gonadotropins shows superior outcomes to letrozole monotherapy 7:

  • Significantly higher ovulation rates (p < 0.001)
  • Significantly higher clinical pregnancy rates (p < 0.001)
  • Improved endometrial thickness and number of mature follicles
  • No significant increase in OHSS or miscarriage rates

Similarly, letrozole combined with clomiphene demonstrates improved mature follicle rates (OR 2.74,95% CI 1.72-4.37) and ovulation rates (OR 2.55,95% CI 1.57-4.12) compared to letrozole alone 8.

Insulin-Sensitizing Agents (Adjunctive Role)

Metformin

While metformin improves ovulation frequency in PCOS, it should not be used as primary ovulation induction therapy 1, 2:

  • Beneficial as adjuvant therapy, particularly in obese women
  • Prevents OHSS in women undergoing IVF (recommended use) 2
  • When combined with clomiphene in clomiphene-resistant women, achieves higher live birth rates (RR 6.4,95% CI 1.2-35) 2
  • Multiple pregnancy rates are lower (around 5%) compared to clomiphene alone 2

Treatment Algorithm for Ovulation Induction

Step 1: Begin with lifestyle modification (5% weight loss improves ovulation and pregnancy rates) 1

Step 2: First-line pharmacotherapy:

  • Letrozole 2.5-5 mg daily for 5 days (preferred based on superior live birth rates) 2, 4, 3
  • Alternative: Clomiphene citrate 50-100 mg daily for 5 days 1

Step 3: If resistant to first-line therapy:

  • Add low-dose gonadotropins (≤75 IU) to letrozole 7
  • Or switch to gonadotropins alone with low-dose protocol 1, 6

Step 4: Consider metformin as adjuvant in obese women or for OHSS prevention 2

Step 5: Laparoscopic ovarian drilling if medical therapy fails (though pregnancy rates lower than gonadotropins: 18% vs 41%) 9

Safety Considerations

Letrozole Safety Profile

Despite historical FDA warnings, high-quality evidence shows letrozole does NOT increase congenital malformation risk 10:

  • Congenital malformation rate: 2.15% (95% CI 1.7-2.5%) - similar to general population
  • No increased risk versus clomiphene (RD 0.01,95% CI -0.02 to 0.03) 10
  • No increased pregnancy loss versus clomiphene 10, 3
  • Lower multiple pregnancy risk due to monofollicular development 4

OHSS Risk

OHSS rates are comparable between letrozole and clomiphene (0.5% in both groups) 3. Gonadotropins carry higher OHSS risk, necessitating low-dose protocols 1, 6.

Common Pitfalls to Avoid

  1. Using high-dose gonadotropins: Doses >75 IU increase multiple pregnancy rates without improving pregnancy rates 6

  2. Avoiding letrozole due to outdated warnings: Current evidence strongly supports its safety and superior efficacy 10, 3

  3. Using metformin as monotherapy for ovulation induction: It's inferior to clomiphene/letrozole and should be adjunctive only 2

  4. Failing to confirm true postmenopausal status: In women with chemotherapy-induced amenorrhea, verify hormonal status before using aromatase inhibitors 11

References

4
Research

Letrozole versus clomiphene citrate for ovulation induction in anovulatory women with polycystic ovarian syndrome: A randomized controlled trial.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2021

8
Research

Letrozole and clomiphene versus letrozole alone for ovulation induction in women with PCOS: a systematic review and meta-analysis.

Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2025

11
Guideline

breast cancer. clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2009

Related Questions

Should letrozole be discontinued until the patient recovers from femur fixation surgery?
What are the maternal and fetal risks associated with pregnancy conceived after artificial ovulation induction (e.g., clomiphene citrate, letrozole, gonadotropins)?
What is the recommended monitoring protocol for a patient receiving letrozole therapy, including baseline labs and follow‑up testing?
If natural ovulation occurs during a break from Letrozole (letrozole), can a patient safely continue without Letrozole (letrozole)?
Can letrozole cause abdominal bloating?
What is the appropriate management of hypothyroidism and what are the associated risk factors?
Is Ritalin LA (methylphenidate extended‑release) still active at 9 am after a dose taken at 3 pm the previous day?
Why did I wake up feeling groggy and irritable after taking Ritalin LA (methylphenidate) at 3 pm?
Are there any studies or guidelines regarding breakthrough herpes zoster in individuals who have received the recombinant zoster vaccine (Shingrix)?
In a 50-year-old male with erectile dysfunction, a good marital relationship, stable life circumstances, borderline hypertension, and obesity, how should a phosphodiesterase‑5 inhibitor be initiated and managed?
What is the likely diagnosis and recommended management for a 6-year-old white child with a few small telangiectasias on the cheek?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.